Alerts , Oil & Gas E&P , Energy , GRNT
Granite Ridge Resources Insider Transaction Report
- Acquired: Non-Derivative
On May 14, 2024, Rachman Ilya M, CEO of Immix Biopharma, Inc. (IMMX), bought 4,300 shares at $2.25 each, totaling $9,288.00. This increased his stake to 912,000 shares. Rachman's history includes significant stock options and share purchases. The company's stock has varied, with a fifty-two-week price change of 81.82% and a market cap of $58,059,244. Another insider, Morris Gabriel S, also invested, buying 4,500 shares at $2.23. These transactions may reflect insider confidence in the company's future.
On May 10, 2024, Topline Capital Management, Llc purchased 30,000 shares of Issuer Direct Corporation (ISDR) at $9.97 per share, totaling $300,000. This reflects ongoing investment, as they previously acquired shares at varying prices, indicating confidence in ISDR's potential. Despite a market downturn, with a -16.32% change recently, Topline's actions suggest an optimistic view of the company's future. Issuer Direct Corporation, a technology firm, has a market cap of USD 66,583,940 and remains financially robust with significant gross profits.
Williamson Robert F III, an insider at Perspective Therapeutics, Inc. (CATX), recently acquired 18,601.2941 shares at $0.71 per share, totaling $13,950.97. This non-derivative transaction suggests a direct and confident investment in the company's future. With a history of consistent share purchases over the past year, Williamson's actions reflect a bullish perspective on the Healthcare sector player. The company's stock has seen a 66.67% rise in the last ten days and a 200.0% surge over fifty days. With a robust market cap of USD 83,189,304 and low debt levels, Perspective Therapeutics stands on solid financial ground, …
In a notable move, Williams Gregg, a major insider at Vivani Medical, Inc. (VANI), has bolstered their holdings with a new acquisition of 7,620 shares at $1.01 each, totaling $7,696.20. This purchase increases Gregg's total ownership to 721,411 shares, showcasing a robust belief in the firm's future. Over the past year, Gregg has consistently invested in VANI, with share prices ranging from $0.86 to $1.08. Amidst the biotech sector's volatility, VANI maintains a steady share price with a market cap of USD 50,818,800, cash reserves of USD 32,486,000, and debt of USD 20,988,000 …
Pages total: 46